研报掘金丨开源证券：维持佐力药业“买入”评级，外延并购打开成长空间

Core Viewpoint - Zhaoli Pharmaceutical plans to acquire a multi-trace element injection asset group from Future Pharmaceutical to enrich its product structure and enhance marketing synergy [1] Group 1: Acquisition Details - The company signed an asset acquisition agreement for the multi-trace element injection group with Tibet Future and its two wholly-owned subsidiaries, Xuchang Future and Hefei Future, for a total price of RMB 356 million (including tax) [1] - The acquisition aims to optimize the company's product structure and expand its treatment areas for diseases [1] Group 2: Market Potential - The multi-trace element injection is a major source of trace elements in parenteral nutrition, with an overall market size projected to reach approximately RMB 1.8 billion in 2024 [1] - The company's advantages in centralized procurement and basic drug products will allow it to leverage its clinical promotion experience for synergistic development with the multi-trace element injection products [1] Group 3: Investment Outlook - The external acquisition opens up growth opportunities for the company, maintaining a "buy" rating [1]